These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 14970856)

  • 1. A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours.
    Wall L; Talbot DC; Bradbury P; Jodrell DI
    Br J Cancer; 2004 Feb; 90(4):800-4. PubMed ID: 14970856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
    Levitt NC; Eskens FA; O'Byrne KJ; Propper DJ; Denis LJ; Owen SJ; Choi L; Foekens JA; Wilner S; Wood JM; Nakajima M; Talbot DC; Steward WP; Harris AL; Verweij J
    Clin Cancer Res; 2001 Jul; 7(7):1912-22. PubMed ID: 11448904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen.
    Primrose JN; Bleiberg H; Daniel F; Van Belle S; Mansi JL; Seymour M; Johnson PW; Neoptolemos JP; Baillet M; Barker K; Berrington A; Brown PD; Millar AW; Lynch KP
    Br J Cancer; 1999 Feb; 79(3-4):509-14. PubMed ID: 10027321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
    Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
    Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of marimastat in advanced pancreatic cancer.
    Evans JD; Stark A; Johnson CD; Daniel F; Carmichael J; Buckels J; Imrie CW; Brown P; Neoptolemos JP
    Br J Cancer; 2001 Dec; 85(12):1865-70. PubMed ID: 11747327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects.
    King J; Zhao J; Clingan P; Morris D
    Anticancer Res; 2003; 23(1B):639-45. PubMed ID: 12680160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
    Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
    Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
    Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial.
    Rosenbaum E; Zahurak M; Sinibaldi V; Carducci MA; Pili R; Laufer M; DeWeese TL; Eisenberger MA
    Clin Cancer Res; 2005 Jun; 11(12):4437-43. PubMed ID: 15958628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
    Ryan QC; Headlee D; Acharya M; Sparreboom A; Trepel JB; Ye J; Figg WD; Hwang K; Chung EJ; Murgo A; Melillo G; Elsayed Y; Monga M; Kalnitskiy M; Zwiebel J; Sausville EA
    J Clin Oncol; 2005 Jun; 23(17):3912-22. PubMed ID: 15851766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I.
    Fouliard S; Robert R; Jacquet-Bescond A; du Rieu QC; Balasubramanian S; Loury D; Loriot Y; Hollebecque A; Kloos I; Soria JC; Chenel M; Depil S
    Eur J Cancer; 2013 Sep; 49(13):2791-7. PubMed ID: 23790467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.
    Wojtowicz-Praga S; Torri J; Johnson M; Steen V; Marshall J; Ness E; Dickson R; Sale M; Rasmussen HS; Chiodo TA; Hawkins MJ
    J Clin Oncol; 1998 Jun; 16(6):2150-6. PubMed ID: 9626215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer.
    Rubin EH; Agrawal NG; Friedman EJ; Scott P; Mazina KE; Sun L; Du L; Ricker JL; Frankel SR; Gottesdiener KM; Wagner JA; Iwamoto M
    Clin Cancer Res; 2006 Dec; 12(23):7039-45. PubMed ID: 17145826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid.
    Eatock M; Cassidy J; Johnson J; Morrison R; Devlin M; Blackey R; Owen S; Choi L; Twelves C
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):39-46. PubMed ID: 15368080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors.
    Fujiwara Y; Yamamoto N; Yamada Y; Yamada K; Otsuki T; Kanazu S; Iwasa T; Hardwick JS; Tamura T
    Cancer Sci; 2009 Sep; 100(9):1728-34. PubMed ID: 19575752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196.
    Sparano JA; Bernardo P; Stephenson P; Gradishar WJ; Ingle JN; Zucker S; Davidson NE
    J Clin Oncol; 2004 Dec; 22(23):4683-90. PubMed ID: 15570070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.
    Rugo HS; Herbst RS; Liu G; Park JW; Kies MS; Steinfeldt HM; Pithavala YK; Reich SD; Freddo JL; Wilding G
    J Clin Oncol; 2005 Aug; 23(24):5474-83. PubMed ID: 16027439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.
    Erlichman C; Hidalgo M; Boni JP; Martins P; Quinn SE; Zacharchuk C; Amorusi P; Adjei AA; Rowinsky EK
    J Clin Oncol; 2006 May; 24(15):2252-60. PubMed ID: 16710023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
    Zhu AX; Clark JW; Ryan DP; Meyerhardt JA; Enzinger PC; Earle CC; Fuchs CS; Regan E; Anbe H; Houghton M; Zhang J; Urrea P; Kulke MH
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):285-93. PubMed ID: 16786333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors.
    Zhu AX; Ready N; Clark JW; Safran H; Amato A; Salem N; Pace S; He X; Zvereva N; Lynch TJ; Ryan DP; Supko JG
    Clin Cancer Res; 2009 Jan; 15(1):374-81. PubMed ID: 19118068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.